CriticalClass III antiarrhythmic, selective IKr blocker×Imidazole antifungal
Updated · Methodology
Mechanism
Dofetilide, a class III antiarrhythmic, blocks the cardiac potassium current IKr, and the QT interval increases linearly with its dose and blood level (dofetilide label, US Food and Drug Administration, FDA). About 80% of a dofetilide dose leaves the body in the urine, partly through active renal secretion of cations, and CYP3A4 metabolises it only to a small extent. Even so, the US label says that CYP3A4 inhibitors, including azole antifungals, may increase dofetilide levels (FDA). The miconazole oral gel summary of product characteristics (SmPC) calls miconazole a clinically potent CYP3A4 inhibitor. It contraindicates oral miconazole with QT-prolonging drugs that this enzyme metabolises, including dofetilide, because their higher levels can prolong the QT interval and cause potentially fatal torsade de pointes (miconazole oral gel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label contraindicates ketoconazole with dofetilide because ketoconazole inhibits renal cation secretion (FDA). The miconazole SmPCs say nothing about such an effect, and the documents give no measurements of dofetilide levels with miconazole (AEMPS). Patients hold the gel in the mouth and then swallow it. A 60 mg dose of the gel gives peak plasma miconazole levels of 31–49 ng/mL (miconazole oral gel SmPC, AEMPS). Less than 1% of a cream dose is absorbed (miconazole cream SmPC, AEMPS). Each Spanish vaginal ovule contains 100 mg of miconazole with 300 mg of metronidazole. Their SmPC gives data for 1200 mg miconazole ovules: levels more than 100 times lower than after oral or intravenous use (vaginal ovule SmPC, AEMPS).
Symptoms
The main risk is QT prolongation and torsade de pointes, which can be fatal (miconazole oral gel summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; dofetilide label, US Food and Drug Administration, FDA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Dofetilide can cause serious ventricular arrhythmias, mainly polymorphic ventricular tachycardia of the torsade de pointes type: in people with supraventricular arrhythmias it occurred in 0.8%, more often at higher doses and mostly within the first three days of treatment (dofetilide FDA label). Reduced creatinine clearance and certain drug interactions raise dofetilide levels, and low potassium and magnesium increase the risk of torsade de pointes (dofetilide FDA label).
Management
The combination is contraindicated for oral miconazole. The miconazole oral gel summary of product characteristics (SmPC) names dofetilide among the QT-prolonging drugs that must not be used with oral miconazole (miconazole oral gel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Patients hold the gel in the mouth and then swallow it, so the contraindication also applies when it is used for oral or oesophageal candidiasis (miconazole oral gel SmPC, AEMPS). Dofetilide is not authorised in Spain. Its US label says that CYP3A4 inhibitors, including azole antifungals, should be given with it cautiously, and that inhibitors of renal cation secretion, such as ketoconazole, are contraindicated (dofetilide label, US Food and Drug Administration, FDA). The miconazole cream and vaginal ovule SmPCs do not mention dofetilide. According to them, little miconazole reaches the blood and clinically relevant interactions are rare. Still, the SmPC of the ovules, which combine miconazole with metronidazole, notes QT prolongation, particularly when metronidazole was given with QT-prolonging drugs (miconazole cream and vaginal ovule SmPCs, AEMPS). Start or restart dofetilide only in a facility that can calculate creatinine clearance, provide continuous electrocardiogram (ECG) monitoring and perform cardiac resuscitation. The patient stays there for at least three days (dofetilide FDA label). Calculate creatinine clearance before the first dose. Dofetilide is contraindicated if the QT or heart-rate-corrected QT interval (QTc) exceeds 440 ms (500 ms with ventricular conduction abnormalities). Bring potassium into the normal range before starting and keep it there throughout treatment (dofetilide FDA label). If at any time after the second dose the QT or QTc exceeds 500 ms (550 ms with conduction abnormalities), stop dofetilide. When stopping dofetilide before a potentially interacting drug, wait at least two days before starting that drug (dofetilide FDA label). For torsade de pointes or overdose, options include an isoprenaline (isoproterenol) infusion, with or without cardiac pacing, and intravenous magnesium sulfate. Keep the patient under close monitoring until the QT interval returns to normal (dofetilide FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Daktarin 20 mg/g gel oral, miconazol (nº registro 55962), sección 4.3 (2026)– AEMPS, CIMA, nº registro 55962 (Daktarin 20 mg/g gel oral, JNTL Consumer Health), revisión 06/2026, secciones 4.3, 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Blasgina óvulos vaginales (nº registro 50441), sección 4.5 (2026)– AEMPS, CIMA, nº registro 50441 (Blasgina óvulos vaginales, Almirall), revisión 09/2026, secciones 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Miconazol crema (nº registro 50271), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 50271 (Daktarin 20 mg/g crema), revisión 06/2026, secciones 4.4, 4.5 y 5.2 (en el HTML de CIMA siguen al apartado 4.3, sin ancla propia)
- FDA: TIKOSYN (dofetilide) capsules prescribing information (2026)– FDA, DailyMed setid 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (Pfizer), revisión 04/2026 (versión 30), Boxed Warning, Contraindications, Warnings (Ventricular Arrhythmia, Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents), Precautions (Drug-Drug Interactions), Dosage and Administration